Monopar Therapeutics NDA Filing Sparks $125 Price Target Adjustment

The recent New Drug Application (NDA) filing by Monopar Therapeutics has prompted a notable reassessment of the company's market position. H.C. Wainwright analysts, responding to the regulatory progress, have adjusted their price target for the stock to $125.…